Nautilus Biotechnology Inc. is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus Biotechnology Inc., formerly known as Arya Sciences Acquisition Corp III, is based in SEATTLE.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-70.78M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.49 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -32.53% |
| Return on Assets (Trailing 12 Months) | -27.85% |
| Current Ratio (Most Recent Fiscal Quarter) | 18.52 |
| Quick Ratio (Most Recent Fiscal Quarter) | 18.52 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.43 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.12 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.56 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.52 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 126.31M |
| Free Float | 74.39M |
| Market Capitalization | $88.73M |
| Average Volume (Last 20 Days) | 0.21M |
| Beta (Past 60 Months) | 1.42 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 41.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 50.71% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |